title: Dynamic Contrast-Enhanced MRI Using a Macromolecular MR Contrast Agent (P792): Evaluation of Antivascular Drug Effect in a Rabbit VX2 Liver Tumor Model.
abstract: OBJECTIVE
  To evaluate the utility of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using macromolecular contrast agent (P792) for assessment of vascular disrupting drug effect in rabbit VX2 liver tumor models.
  
  
  METHODS
  This study was approved by our Institutional Animal Care and Use Committee. DCE-MRI was performed with 3-T scanner in 13 VX2 liver tumor-bearing rabbits, before, 4 hours after, and 24 hours after administration of vascular disrupting agent (VDA), using gadomelitol (P792, n = 7) or low molecular weight contrast agent (gadoterate meglumine [Gd-DOTA], n = 6). P792 was injected at a of dose 0.05 mmol/kg, while that of Gd-DOTA was 0.2 mmol/kg. DCE-MRI parameters including volume transfer coefficient (K(trans)) and initial area under the gadolinium concentration-time curve until 60 seconds (iAUC) of tumors were compared between the 2 groups at each time point. DCE-MRI parameters were correlated with tumor histopathology. Reproducibility in measurement of DCE-MRI parameters and image quality of source MR were compared between groups.
  
  
  RESULTS
  P792 group showed a more prominent decrease in K(trans) and iAUC at 4 hours and 24 hours, as compared to the Gd-DOTA group. Changes in DCE-MRI parameters showed a weak correlation with histologic parameters (necrotic fraction and microvessel density) in both groups. Reproducibility of DCE-MRI parameters and overall image quality was not significantly better in the P792 group, as compared to the Gd-DOTA group.
  
  
  CONCLUSIONS
  Dynamic contrast-enhanced magnetic resonance imaging using a macromolecular contrast agent shows changes of hepatic perfusion more clearly after administration of the VDA. Gadolinium was required at smaller doses than a low molecular contrast agent.
authors.affiliation: Department of Radiology, Konkuk University School of Medicine, Seoul 05030, Korea.
authors.forename: Hee Sun
authors.initials: HS
authors.lastname: Park
authors.affiliation: Department of Radiology and Institute of Radiation Medicine, Seoul National University Hospital, Seoul 03080, Korea.
authors.forename: Joon Koo
authors.initials: JK
authors.lastname: Han
authors.affiliation: Department of Radiology and Institute of Radiation Medicine, Seoul National University Hospital, Seoul 03080, Korea.
authors.forename: Jeong Min
authors.initials: JM
authors.lastname: Lee
authors.affiliation: Department of Radiology, Sheikh Khalifa Specialty Hospital, Ras Al Khaimah, United Arab Emirates.
authors.forename: Young Il
authors.initials: YI
authors.lastname: Kim
authors.affiliation: Department of Radiology and Institute of Radiation Medicine, Seoul National University Hospital, Seoul 03080, Korea.
authors.forename: Sungmin
authors.initials: S
authors.lastname: Woo
authors.affiliation: Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Korea.
authors.forename: Jung Hwan
authors.initials: JH
authors.lastname: Yoon
authors.affiliation: Department of Radiology, Yonsei University College of Medicine, Seoul 03722, Korea.
authors.forename: Jin-Young
authors.initials: JY
authors.lastname: Choi
authors.affiliation: Department of Radiology and Institute of Radiation Medicine, Seoul National University Hospital, Seoul 03080, Korea.
authors.forename: Byung Ihn
authors.initials: BI
authors.lastname: Choi
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001577:Benzophenones / Q000627:therapeutic use; D004195:Disease Models, Animal; D006571:Heterocyclic Compounds / Q000008:administration & dosage / Q000737:chemistry*; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008297:Male; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000737:chemistry*; D011817:Rabbits; D011859:Radiography; D015203:Reproducibility of Results; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001577:Benzophenones; D006571:Heterocyclic Compounds; C552333:N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide; D009942:Organometallic Compounds; C050823:gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate; D014633:Valine; C435266:contrast agent P792
keywords: Animal experimentation; Antitumor agents; Contrast agents; Liver neoplasms; Magnetic resonance imaging